SCHEDULE: FMR LLC Reports Stake in Structure Therapeutics

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 13.2% in Structure Therapeutics Inc. as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Structure Therapeutics Inc. common stock.
• As of June 30, 2026, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 28,197,369 shares.
• This represents 13.2% of the class of securities.
• FMR LLC, organized in Delaware, is classified as a holding company (HC).
• Abigail P. Johnson, a US citizen, is classified as an insider (IN) in relation to FMR LLC.
• The filing indicates that FMR LLC has sole voting and dispositive power over the shares.
• Several entities are listed as subsidiaries or affiliates of FMR LLC involved in the beneficial ownership, including Crosby Advisors LLC, FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited, and IMPRESA MANAGEMENT LLC.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than company performance or strategic shifts.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant stake, indicating continued investor confidence or strategic interest.
• The filing is a routine disclosure, suggesting no immediate negative corporate events.

Negatives

• The filing does not provide any financial performance data or operational updates for Structure Therapeutics Inc.

Risks

• The filing does not explicitly mention any risks related to Structure Therapeutics Inc.'s operations or market position.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Structure Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to report their holdings. This filing indicates FMR LLC's continued substantial investment in Structure Therapeutics Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: The continued significant stake by FMR LLC and Abigail P. Johnson may be viewed positively, suggesting stability and institutional support.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any changes in their beneficial ownership as required by SEC regulations.

Key Dates

Keywords

Structure Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment Management, Fidelity